What is Xarelto?
The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 as a more convenient alternative to Coumadin (warfarin), the traditional blood thinner that has been used since the 1950s to prevent heart attacks, strokes, and blood clots.
Although all blood thinners increase the risk of bleeding problems, Xarelto has been linked to an increased number of uncontrollable blood injuries, mostly because there is no approved antidote available for patients who use the medication, and many of the side effects have been severe because the bleeding cannot be effectively controlled.
Since Xarelto’s approval five years ago, thousands of Xarelto lawsuits have been filed against drug makers Johnson & Johnson and Bayer AG, alleging Xarelto side effects including:
- Gastrointestinal bleeding
- Rectal bleeding
- Internal bleeding
- Heart attack
- Pulmonary embolism
- Epidural hematoma
- Brain hemorrhages.
Some 2,800 Xarelto lawsuits have been consolidated into multidistrict litigation (MDL) in Eastern Louisiana and nearly 700 have been combined into a mass tort program in the state of Pennsylvania.
Xarelto lawyers will continue to file cases on behalf of individuals experiencing uncontrolled bleeding events while on the blood thinner while the bellwether trials move forward in February 2017.
Please share Lawsuits Question Xarelto Risk While FDA Assures Public of Xarelto Clinical Trial Data with individuals who are worried about the dangers of Xarelto.